Newsletter · · Ashutosh Agarwal
Thermo Fisher Pushes the Connected Lab Software Annuity - Life-Science Tools Recovery - Week of June 28, 2026
For the week of June 21-28, 2026, Thermo Fisher's David Hardy laid out a connected-lab, standards-led software and services strategy on the Smart Biotech Scientist podcast, a recurring-revenue play layered on the installed base.
Life-Science Tools Recovery
Week of June 28, 2026: Thermo Fisher Pushes the Connected Lab Software Annuity
TL;DR
- The week's substantive operator voice was Thermo Fisher's David Hardy, who used a two-part podcast appearance to make a software-and-services pitch rather than a demand update. The takeaway is a mix story, not an order-book story.
- Hardy framed the connected lab as commercial today, not roadmap, and positioned digital transformation as a sticky, multi-year annuity layered on the installed base, accretive to mix and recurring revenue but a slow burn rather than a 2026 catalyst.
- He also planted a flag on data standards (Allotrope's ASM format), arguing standardization is the substrate for predictive ML, a quiet bid to make Thermo's outputs the default as labs adopt AI.
What's New
Thermo Fisher leans into the "connected lab," a mix story, not a demand story. David Hardy, Market and Innovation Strategist at Thermo Fisher Scientific (TMO), appeared across a two-part series on Smart Biotech Scientist, Ep. 263 (June 23) and Ep. 264 (June 25). This is a software-and-services pitch, not a demand update: no guidance, no order trends, no consumables data. But it tells you where Thermo is steering the attach-rate narrative.
Hardy's diagnosis of the customer pain point is vivid:
"You walk into a state of the art biotech lab, you'll see millions in equipment, some of the sharpest minds in science, and half the data is trapped in spreadsheets no one else can read. Data lives in silos, spreadsheets bridge the gaps, automation projects stall before they start."
Two things matter for the model. First, Hardy was explicit that this is commercial today, not roadmap: Thermo has "several customer experience centers around the world where customers can come in and see that lab today... that's something that we can very much do today and demonstrate." Second, he repeatedly framed digital transformation as a "long game... not something that can be done necessarily in six months," with the main customer pushback being "oh, we have to keep doing this for a longer time and there's a commitment to it." Translation: a sticky, multi-year software and services annuity layered on top of the instrument base, accretive to mix and recurring revenue, but a slow burn, not a 2026 catalyst. He also planted a flag on data standards (Allotrope's ASM format), arguing "standardization is the key to enabling AI," a quiet bid to make Thermo's outputs the default substrate as labs adopt predictive ML, which he notably separated from the generative-AI hype: "the traditional ML, the predictive AI, so to speak, is still the backbone of AI."
The Debate
The bull (bioprocessing/CGT/NGS re-accel): The recovery thesis rests on consumables re-stocking, CDMO capacity filling, and CGT industrializing, and the structural reshoring and capability-shift narrative from prior weeks still stands. Thermo's confident push into a recurring software annuity is consistent with a management team that believes the installed base is healthy enough to monetize further.
The bear (China/academic/tariff/lumpy capex): The connected-lab pitch monetizes existing demand, it does not create new demand. The software annuity is real but slow-burning, and it does nothing to resolve the near-term questions on bioprocessing book-to-bill, China exposure, or lumpy capex that will be settled at the prints, not in a strategy conversation.
Our read: Thermo's strategy update is a positive signal on mix and stickiness over time, but it does not change the near-term demand picture. The next hard data point is Q2.
Stocks in Play
Thermo Fisher was the coverage name discussed with substance this week.
| Ticker | This week's signal | Bull case | Bear case | Next catalyst |
|---|---|---|---|---|
| TMO (Thermo Fisher) | Operator: Hardy on connected-lab/digital strategy. Product-strategy only, no financials. | Recurring software and services annuity on top of installed base; standards land-grab (ASM) deepens switching costs and mix. | Multi-year, slow-burn sales cycle; this monetizes existing demand, it doesn't create new demand. No 2026 numbers attached. | Q2 FY26 earnings (late July) |
Read-Throughs
- Thermo Fisher specifically: The actionable read-through is qualitative. TMO is pressing a recurring-revenue, standards-led software strategy that should support mix and stickiness over time. It does not change the near-term demand picture.
- Bioprocessing peers (Sartorius, Repligen, Avantor, Maravai) and sequencing (ILMN, PACB, TXG): The qualitative case for monetizing the installed base applies most directly to Thermo; the broader demand questions across these names remain to be settled at the Q2 prints (late July to early August).